AI Article Synopsis
- TLR4 is important for the innate immune system and is linked to the development of various diseases.
- A new antibody, 52-1H4 e2 (e2), successfully blocked interleukin-6 secretion triggered by lipopolysaccharides.
- In rats, the antibody maintained a serum concentration above 10 μg/mL for 28 days, suggesting it could be valuable for studying TLR4's role in disease models.
Article Abstract
Toll-like receptor 4 (TLR4) plays a critical role in the innate immune system and is involved in the pathogenesis of multiple diseases. Here, we report the antagonistic and ratized antibody, 52-1H4 e2 (e2), which completely inhibited lipopolysaccharide-induced interleukin-6 secretion . The average serum drug concentration was above 10 μg/mL for 28 days in rats injected with e2. The novel anti-rat TLR4/myeloid differentiation factor 2 antibody, e2, may be a useful tool for investigating the role of TLR4 in rat disease models.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/mab.2020.0020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunohistochemistry of Immune Cells and Cells Bound to Administered Antibodies in Liver, Lung, Pancreas, and Colon of B6/lpr Mice.
Bio Protoc
July 2022
Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York, USA.
Employing a novel mouse model of immune related adverse events (irAEs) induced by combination of anti-PD1 and anti-CTLA-4 antibodies, we visualized immune infiltration into the liver, lung, pancreas, and colon. Here, we describe the avidin-biotin conjugate (ABC) method used to stain T cells (CD4 and CD8), B cells (CD19), macrophages (F4/80), and cells bound by the administered rat anti-mouse antibodies for chromogenic immunohistochemistry (IHC). Using a biotinylated goat anti-rat antibody, we detected the localization of cells bound to the antibodies for PD-1 and CTLA-4.
View Article and Find Full Text PDFEOS789, pan-phosphate transporter inhibitor, ameliorates the progression of kidney injury in anti-GBM-induced glomerulonephritis rats.
Pharmacol Res Perspect
June 2022
Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Hyperphosphatemia associated with chronic kidney disease (CKD) not only dysregulates mineral metabolism and bone diseases, but also strongly contributes to the progression of kidney disease itself. We have identified a novel drug for hyperphosphatemia, EOS789, that interacts with several sodium-dependent phosphate transporters (NaPi-IIb, PiT-1, and PiT-2) known to contribute to intestinal phosphate absorption. In this study, we investigated whether EOS789 could ameliorate kidney disease progression in glomerulonephritis rats.
View Article and Find Full Text PDFNeuronal internalization of immunoglobulin G injected into the mouse brain by a novel absorption strategy to avoid unwanted interaction with immune complex using centrifugal filtration.
Histochem Cell Biol
August 2022
Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.
Monoclonal immunoglobulin-G (IgG) antibodies are now emerging as therapeutic tools to tackle various disorders, including those affecting the brain. However, little is known about how these IgG molecules behave in the brain. To better understand the potential behavior of IgG molecules in the brain, here we established a specific protocol to immunolocalize rat IgG injected into mouse striatum with an anti-rat IgG antibody.
View Article and Find Full Text PDFNanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design.
Acta Pharm Sin B
October 2021
Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan 430030, China.
Acute respiratory distress syndrome (ARDS) is characterized by the severe inflammation and destruction of the lung air-blood barrier, leading to irreversible and substantial respiratory function damage. Patients with coronavirus disease 2019 (COVID-19) have been encountered with a high risk of ARDS, underscoring the urgency for exploiting effective therapy. However, proper medications for ARDS are still lacking due to poor pharmacokinetics, non-specific side effects, inability to surmount pulmonary barrier, and inadequate management of heterogeneity.
View Article and Find Full Text PDFGeneration and Characterization of a Novel Anti-Rat TLR4/MD2 Antibody with Potent Neutralizing Activity .
Monoclon Antib Immunodiagn Immunother
December 2020
Drug Discovery Research, Astellas Pharma, Inc., Tsukuba, Ibaraki, Japan.
Article Synopsis
- TLR4 is important for the innate immune system and is linked to the development of various diseases.
- A new antibody, 52-1H4 e2 (e2), successfully blocked interleukin-6 secretion triggered by lipopolysaccharides.
- In rats, the antibody maintained a serum concentration above 10 μg/mL for 28 days, suggesting it could be valuable for studying TLR4's role in disease models.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!